Interferon-induced transmembrane (IFITM) proteins are a family of viral restriction factors that inhibit the entry processes of several pathogenic viruses, including influenza A virus (IAV), in vitro. Here we report that IAV-infected knockout mice lacking the Ifitm locus on chromosome 7 exhibited accelerated disease progression, greater mortality, and higher pulmonary and systemic viral burdens as compared to wild type controls. We further observed that the phenotype of Ifitm3-specific knockout mice was indistinguishable from that of mice lacking the entire Ifitm locus. Ifitm3 was expressed by IAV target cells including alveolar type II pneumocytes and tracheal/bronchial respiratory epithelial cells. Robust Ifitm3 expression was also observed in several tissues in the absence of infection. Among murine Ifitm promoters, only that of Ifitm3 could be induced by type I and II interferons. Ifitm3 could also be upregulated by the gp130 cytokines IL-6 and oncostatin M on cells expressing appropriate receptors, suggesting that multiple cytokine signals could contribute to Ifitm3 expression in a cell or tissue-specific manner. Collectively, these findings establish a central role for Ifitm3 in limiting acute influenza in vivo, and provide further insight into Ifitm3 expression and regulation.
Introduction
The interferon-induced transmembrane (IFITM) proteins are a family of small transmembrane proteins that mediate some of the antiviral activities of type I and II interferons [1, 2, 3] . IFITMmediated restriction is specific to particular virus families. Influenza A viruses (IAV), Ebola virus (EBOV), Marburg virus (MARV), SARS coronavirus (SARS-CoV), dengue virus, and West Nile virus are all efficiently restricted by one or more IFITM family proteins. Conversely, IFITM proteins do not restrict murine leukemia virus (MLV), a range of alphaviruses, and arenaviruses including Machupo virus (MACV), Lassa virus (LASV), and lymphocytic choriomeningitis virus (LCMV) [2, 4, 5] . Vesicular stomatitis virus is inefficiently restricted [6, 7] . Two groups have reported cell line-specific restriction of HIV-1 [1, 8] , but these reports differ as to which cell lines show efficient restriction. Restriction activity against non-enveloped viruses has not been reported to date.
The mechanism of action of IFITM-mediated restriction has not yet been determined. Multiple lines of evidence indicate that restriction occurs after virion endocytosis but during or prior to membrane fusion. IFITM proteins prevent infection by retroviruses pseudotyped with entry proteins of IFITM-restricted viruses, but not those pseudotyped with entry proteins of unrestricted viruses [4] . Entry assays using virions containing b-lactamase-Vpr (BlaM-Vpr) fusion proteins likewise reveal that IFITM proteins prevent transfer of BlaM-Vpr to the cytosol of target cells [8] . Previously, we showed by fluorescent microscopy that labeled IAV virions are internalized normally and traffic to acidified endocytic compartments despite IFITM expression [4] , a conclusion confirmed and extended by Feely et al. using a rigorous set of imaging studies. They further demonstrated by fluorescent in situ hybridization that IFITM proteins cause sequestration and accumulation of IAV genetic material in late endocytic/lysosomal compartments [9] .
IFITM proteins also localize to late endosomes/lysosomes as demonstrated by co-localization with LAMP1, LAMP2, and CD63 [4] . Moreover, IFITM protein over-expression -and in some cell lines, interferon treatment -results in enlargement of these organelles [9] . Finally, a recent report showed that endosomes in interferon-treated Ifitm knockout cells are inefficiently acidified and suggested that a physical association between Ifitm3 and a subunit of the vacuolar ATPase complex mediates this effect [10] . It appears, therefore, that IFITM proteins alter the properties of late endosomes and lysosomes, and render these organelles inhospitable to viral fusion. Such a model is supported by the pattern of IFITM-mediated restriction; excepting HIV-1, restricted viruses generally fuse late in the endocytic pathway whereas unrestricted viruses fuse at the plasma membrane or in early endocytic compartments. Further evidence that restriction depends on the site of viral fusion comes from investigation of SARS-CoV. SARS-CoV requires lysosomal cathepsins to activate its entry protein and fuse with the lysosomal membrane [11] . Treating receptor-bound virions with trypsin, however, removes this cathepsin dependency, induces fusion at the plasma membrane, and bypasses IFITM-mediated entry restriction [4] .
Most vertebrates have two or more IFITM genes [12] . The human IFITM family is composed of four functional genes, IFITM1, 2, 3, and 5. Murine Ifitm1, 2, 3, and 5, located on chromosome 7, are clear orthologs of their human counterparts but mice possess two additional loci: Ifitm6, also located on chromosome 7, and Ifitm7, a retrogene on chromosome 16 [13] . The proteins expressed by these genes restrict influenza A virus (IAV), filovirus, flavivirus, and SARS coronavirus entry in vitro with varying efficiencies [4, 6] . Ifitm5 expression is limited to bone [14, 15] , and the roles of Ifitm6 and 7 are not yet clear. Two strains of knockout mice were used in the following experiments. IfitmDel mice lack Ifitm1, 2, 3, 5, and 6 and Ifitm3egfp mice lack Ifitm3 alone [13] .
The aim of the present study was to determine the in vivo contribution of the Ifitm proteins to the innate immune control of IAV. We show that Ifitm3 alone makes a significant contribution to the control of influenza in mice and provide further insight into its expression and regulation.
Results/Discussion

Murine Ifitm proteins are protective against influenza in vivo
To determine the in vivo relevance of Ifitm proteins, we challenged cohorts of IfitmDel, wild type, and heterozygous male mice with intranasal doses of either 500 or 1000 PFU of influenza A/PR/8/34 (H1N1) (PR8). In accordance with institutional policies, mice were considered moribund and euthanized upon loss of 20% of initial body weight, defined as the 2-day average of their pre-inoculation weights. At both challenge doses, knockout mice exhibited significantly accelerated disease progression and mortality compared to wild type controls ( Figure 1A ). Heterozygotes had an intermediate phenotype. A modest but insignificant difference was observed in the mean survival time of knockout mice receiving each challenge dose, with mice receiving 1000 PFU surviving 0.7 days longer. With the 500 PFU challenge dose, two of five wild type animals survived acute infection but disease remained uniformly lethal in knockout mice. Weight loss at days 3 and 5 was significantly increased in IfitmDel and heterozygous animals as compared to wild type controls ( Figure 1B ; plots of body weight in Figure S1A ).
Weight loss in wild type animals receiving a 500 PFU challenge followed trends reported by other investigators [16] . Price et al. found that mice generally maintained body weight until day 4-5 post-infection, after which they underwent a rapid period of weight loss that continued until day 8-9. The rapid clinical progression beginning on day 4-5 coincided with the onset of cellular and humoral immunity while recovery on day 8-9 corresponded to clearance of the virus. In contrast to wild type animals, IfitmDel mice began a steep decline in weight beginning on day 2 consistent with a failure of innate control of early infection. The variability in the rate of disease progression of knockout mice was also far lower than that of both wild type and heterozygous animals ( Figure S1A ). These results demonstrate that Ifitm proteins mediate innate immunity to influenza A virus during acute infection and that the effect of their deletion is powerful enough to overwhelm other sources of experimental variation. The intermediate phenotype of heterozygous animals shows that gene dosage is important for Ifitm protein-mediated viral restriction. The requirement for high gene dosage may also explain the duplication of the Ifitm alleles observed in multiple species.
Viral loads are higher in infected IfitmDel knockout mice Viral loads were measured in a separate cohort of mice euthanized three days after infection, the period during which body weights of wild type and IfitmDel animals diverge ( Figure  S1A ). Weight loss trends in this cohort of animals were similar to those of previous cohorts ( Figure S1B ). Viral loads, as assessed by real-time RT-PCR of lung RNA, were 2.7-fold higher on average (p = 0.0159) in IfitmDel mice as compared to wild type controls ( Figure 1C ). Differences in splenic viral loads ( Figure 1C ) were similarly increased (15.9-fold, p = 0.0079).
Although the relative difference in splenic viral loads was high, IAV genome copy numbers in the spleen were on the order of 10 4 to 10 5 times lower than those in the lung ( Figure S1C ) and genome expression in the spleens of wild type animals was barely above the detection threshold of our assay. Similarly, we did not identify splenic lesions or any other lesions beyond those in the lungs, trachea, and nasal passages, consistent with the dependence of PR8 hemagglutinin on respiratory proteases for cleavage and activation [17, 18, 19, 20] . We therefore speculate that increased splenic viral loads in knockout mice are a result of more robust infection in the lung and subsequent leakage of virus or viral debris into the periphery.
Ifitm3-specific and IfitmDel knockout mice are equally susceptible to IAV infection Previously, we reported that murine embryonic fibroblasts (MEFs) derived from IfitmDel knockout mice are highly susceptible to IAV and that both baseline and interferon-induced Ifitm protein expression contribute to the IAV resistance in wild type MEFs [2] . Ifitm3 expression alone was sufficient to restore IAV entry restriction to knockout fibroblasts [9] . We have shown that over-expression of most murine Ifitm proteins in a human cell line confers some level of IAV restriction but that Ifitm3 is most effective while Ifitm5, 6, and 7 posses comparatively little activity [4] . We confirmed this observation in the context of IfitmDel MEFs ( Figure S2A) ; again murine Ifitm3 demonstrated the most potent IAV restriction activity regardless of HA type, likely in part due to its higher steady-state expression level ( Figures S2B  and S2C ).
Although Ifitm3 most effectively restricts IAV in vitro, most human and murine Ifitm proteins restrict IAV to some extent when over-expressed [4] . To determine the specific in vivo contribution of Ifitm3, we performed an additional intranasal challenge of wild type, IfitmDel, and Ifitm3-specific (Ifitm3egfp) knockout mice with 500 PFU of PR8. Mortality and weight loss trends of IfitmDel and wild type animals were similar to those of Figure 1 above. Survival times of Ifitm3-specific knockout mice were not significantly different from those of IfitmDel knockout
Author Summary
The human genome contains many genes devoted to combating viral infections. Some of these genes encode a family of proteins called interferon-induced transmembrane (IFITM) proteins which were recently discovered to inhibit infection by influenza A viruses in cell culture experiments. Here we show that genetically engineered mice lacking the murine equivalents of the human IFITM genes are more susceptible to influenza than mice with a full complement of these genes. In addition, deletion of one of these genes alone, Ifitm3, made mice equally susceptible to infection, showing that the Ifitm3 protein plays a central role in the control of influenza A virus in living animals. We also show that murine Ifitm proteins are expressed on cells targeted by influenza A viruses and that the control of their expression in animals is more complex than suggested by previous cell culture studies. mice (p = 0.5380) and the weight loss curves for these two genotypes were superimposed (Figures 2A and B) . As with the IfitmDel mice, heterozygotes of the Ifitm3-specific knockout mice exhibited an intermediate phenotype. We therefore conclude that, among Ifitm proteins, only Ifitm3 makes a substantial contribution to PR8 resistance in vivo.
challenged with 1000 PFU and open symbols represent animals challenged with 500 PFU. At both time points, weight loss differences between any two genotypes were statistically significant (Mann Whitney U test). Bars show mean 6 SEM. (C) Pulmonary and systemic viral loads were measured at 3 DPI from animals challenged with 500 PFU of PR8. The relative abundance of IAV M2 transcript levels from total lung or spleen RNA, normalized to endogenous Gapdh transcript, is shown. Values represent fold changes relative to the mean viral burden of wild type mice. Pulmonary viral loads were 2.7-fold higher in knockout than in wild type controls (p = 0.0159, Mann Whitney U test). Error bars show mean 6 SEM. Splenic viral loads were 15.9-fold greater in knockout than wild type animals (p = 0.0079), but splenic viral loads of wild type animals were barely above the detection threshold of the assay. Splenic viral loads of heterozygotes were not significantly different from those of wild type or knockout animals but a nonsignificant trend was evident across all three genotypes. doi:10.1371/journal.ppat.1002909.g001 
Ifitm3 expression is both cell-type and cytokine dependent
Because the Ifitm3 promoter is sensitive to interferon signaling we reasoned that other Jak/STAT-mediated cytokines might likewise induce Ifitm3 expression. We tested the ability of a type III interferon (IFNl2), the acute phase cytokine IL-6, and oncostatin M (OSM), a cytokine released from activated dendritic cells that synergizes with type I interferon [21] , to upregulate Ifitm3 expression. The latter two molecules belong to a diverse family of cytokines that signal through hetero-or multimeric receptors that activate the Jak/STAT pathway via a common gp130 subunit [22] . Consistent with previous studies, type I and type II interferons induced Ifitm3 expression in both NIH 3T3 murine fibroblasts, and the murine macrophage cell line, RAW264.7. IFNl2 was ineffective, likely due to lack of the appropriate receptor. In 3T3 cells, however, oncostatin M (OSM) induced strong Ifitm3 expression and IL-6 was a potent inducer of Ifitm3 expression and in RAW264.7 cells ( Figure 3A) . The ability of these two cytokines to modulate Ifitm3 expression correlated with the surface expression of their cognate receptors ( Figure 3B) , and was not due to increased expression of type I or II interferons ( Figure S3 ). These data raise the possibility that other gp130-mediated cytokines such as IL-11, IL-27, and LIF could modulate basal and inducible Ifitm3 expression in cells bearing appropriate receptors. Furthermore, they indicate greater specificity and complexity in the regulation of Ifitm3 expression, and possibly other interferon-stimulated genes, than previous studies have implied.
Human IFITM1, 2, and 3 are interferon-stimulated genes [23] . Murine Ifitm3 is shown to be interferon-inducible but the regulation of the other murine Ifitms, particularly the mousespecific family members Ifitm6 and 7, has not been studied. Therefore, we assayed the responsiveness of the murine Ifitm promoters to both type I and type II interferons ( Figure 3C ). We observed that, of the murine Ifitm genes, Ifitm3 alone has an interferon-inducible promoter. Figure 3C also suggests that -at least under these tissue culture conditions -Ifitm promoters may be constitutively active, perhaps contributing to an intrinsic antiviral state. We validated the results of this promoter assay by analyzing cytokine-mediated upregulation of murine Ifitm1, 2, and 3 transcripts by qRT-PCR. Consistent with the promoter studies, and in contrast to the behavior of their human orthologs, murine Ifitm1 and 2 were unresponsive to both type I and type II interferons. Ifitm3 transcript levels were significantly upregulated by both IFNa2 and IFNc in both NIH 3T3 and RAW264.7 cells. Ifitm3 was similarly induced by OSM in 3T3 cells and IL-6 in RAW cells consistent with both western blot and promoter data ( Figure 3D ). Ifitm1 also appeared to respond to OSM stimulation although this increase was not statistically significant.
Ifitm3 localization is consistent with its role as an IAV restriction factor
The data in Figures 2 and 3 show that Ifitm3 is the most potent IAV restriction factor of the murine Ifitm proteins and that Ifitm3 expression alone is efficiently induced interferons. To determine where and under what conditions Ifitm3 is expressed in vivo, we performed comprehensive immunohistochemical staining of the lungs of infected and uninfected wild type mice to determine baseline and influenza-induced patterns of Ifitm3 expression. Contrary to expectations, constitutive expression of Ifitm3 was seen in many lung tissues; marked induction was seen only in the respiratory epithelium of lower airways ( Figure 4A, B, C) . The pattern of distribution was similar in the remaining lung tissue in IAV-infected and uninfected mice. Constitutive expression was observed in respiratory epithelial cells of the upper airways ( Figure 4D, E, F) , the visceral pleura ( Figure 4G, H, I ), and in leukocytes ( Figure 4J , K, L), suggesting that Ifitm3 may provide protection against influenza prior to the interferon and acutephase responses. No immunostaining of Ifitm3-specific knockout mice was observed, confirming the specificity of the antibody for Ifitm3 ( Figure S4) .
We also localized Ifitm3 expression specifically to influenza A virus target cells -alveolar type II pneumocytes and ciliated respiratory epithelial cells [24] -by immunofluorescence and confocal microscopy. Type II pneumocytes were identified by DC-LAMP expression, a marker of type II pneumocyte-specific lysosome-related organelles [25] . Ifitm3 is not only expressed by DC-LAMP positive cells but also colocalizes with DC-LAMP itself, consistent with previous in vitro reports of its localization to endosomal/lysosomal membranes ( Figure 5A ). In contrast, ciliated respiratory epithelium shows intense labeling of the apical cytoplasm or plasma membrane rather than the punctate intracytoplasmic distribution typical of lysosomes (demonstrated by lysosomal marker MAC-3; Figure 5B ). Whether Ifitm3 functions differently in the context of these cells or its apical localization is the end result of endo/lysosomal exocytosis is unknown.
While this manuscript was under review, Everitt et al. published data showing that Ifitm3-specific knockout mice are more susceptible to infection with influenza A virus X31 (H3N2) than wild type controls [26] . They also identified and characterized a polymorphism in human IFITM3 associated with reduced restriction activity and found an increased prevalence of this mutant allele in patients hospitalized for influenza. Our data support and extend the core conclusions of their mouse studies. We further show that mice lacking entire Ifitm locus exhibit a nearly identical disease course to those lacking Ifitm3 alone, and that their respective heterozygote littermates exhibit a phenotype intermediate between knockout and wild type mice. Morever, Ifitm3 is expressed on key IAV target cells in the lungs, and among murine Ifitms, is uniquely induced by type I and II interferons. Collectively these data make clear a primary role for Ifitm3 in the control of influenza A virus in mice.
We also show that many tissues express basal levels of Ifitm3 proteins, and that at least two gp130-family cytokines -OSM and IL-6 -can induce its expression, even in the absence of an interferon response. These results suggest greater complexity in the in vivo regulation of other well-characterized interferon-stimulated genes as well. We further noted Ifitm3 expression in cell populations that are not major IAV targets such as macrophages and endothelial cells. This implies that Ifitm3 deletion will likely enhance susceptibility to infections by monocyte-tropic flaviviruses and macrophage-and endotheliotropic filoviruses.
Our results may also have implications for treatment of viral infections. The fact that Ifitm3 expression can be induced by gp130-mediated cytokines may allow for modulation of its expression in a more targeted, less pleiotropic way by agonizing or antagonizing cell type-specific gp130 heterodimeric receptors. More generally, our findings suggest that pharmacologic induction of human IFITM3 expression or emulation of IFITM3 activity could provide a broad-spectrum therapeutic approach to the treatment of a range of human pathogenic viruses.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of 
Influenza A virus
Human influenza virus A/PR/8 (H1N1) propagated in chicken eggs and sucrose gradient purified from allantoic fluid was obtained from Charles River Laboratories, aliquoted, and frozen. Titer was determined by standard plaque assay on Madin-Darby canine kidney cells.
Mice and inoculations
Heterozygous IfitmDel and Ifitm3egfp mice (background strain C57BL/6J-Tyrc-2J/J) were generously provided by Dr. David Adams (The Wellcome Trust Sanger Institute, Cambridge, United Kingdom). These animals were housed under specific pathogenfree conditions prior to infection. All mice were between 8 and 10 weeks old with the exception of three 12-week-old littermates (one of each genotype) used in Figure 1A of normal saline. Anesthetized mice were inoculated intranasally with influenza A virus diluted in 50 ml of phosphate-buffered saline divided evenly between both nostrils and administered over the course of one to two minutes. Animals were weighed once daily and, per institutional requirements, euthanized upon loss of 20% of initial body weight or when deemed moribund based on clinical signs. All procedures were performed with the approval of Harvard University's Institutional Animal Care and Use Committee.
Viral load measurements
Lungs and spleens were harvested, rapidly frozen, and stored at 280uC prior to RNA isolation. Tissue was thawed in RNALater, transferred to 1 ml (lungs) or 0.5 ml (spleens) of RNAase-free water and mechanically homogenized with a QIAGEN TissueRuptor. RNA extraction was performed by means of the QIAGEN RNeasy Tissue Kit and QIAshredder columns (QIAGEN). Viral loads were determined by real-time TaqMan RT-PCR. Influenza A viral M2-specific primer and probe sequences were adapted for use with IAV PR/8/34 from protocols developed by the Centers for Disease Control [27] . Sequences were: 59-GAC CAA TCC TGT CAC CTC TGA C-39 (forward primer), 59-AGG GCA TTT TGG ACA AAG CGT CTA-39 (reverse primer), and 59-TGC AGT CCT CGC TCA CTG GGC ACG-39 (probe). Reporter and quencher dyes were FAM and IBFQ respectively with an additional internal Zen Quencher (Integrated DNA Technologies). Similarly labeled Gapdh primer and probe sequences were: 59-GTG GAG TCA TAC TGG AAC ATG TAG-39 (forward primer), 59-AAT GGT GAA GGT CGG TGT G-39 (reverse primer), and 59-TGC AAA TGG CAG CCC TGG TG-39 (probe) (Integrated DNA Technologies). 25 ml reactions containing 25 ng RNA, 50 pmol each primer, and 25 pmol probe were prepared using the Superscript III One-Step RT-PCR System with Platinum Taq DNA Polymerase and ROX (Invitrogen). Cycling conditions were: 50uC for 30 min (reverse transcription), 95uC for 2 min (denaturation), and 45 cycles of 95uC for 15 seconds (dentaturation) and 55uC for 45 sec (annealing, extension, and fluorescence acquisition). Cycling and fluorescence detection were performed in an ABI Prism 7500 thermal cycler (Applied Biosystems).
Pseudovirus entry assays
Entry assays were performed on murine embryonic fibroblasts (MEFs) derived from IfitmDel knockout mice. Cells were transduced with retroviral puromycin-selectable vectors encoding the murine Ifitm proteins or with an empty vector control, as previously described [4] . MEFs were cultured for one week in puromycin to correct for variation in transduction efficiency. GFPencoding retroviruses pseudotyped with PR8 neuraminidase and IAV HA (derived from influenza A/PR/8/34 (H1N1), influenza A/Thailand/2(SP-33)/2004 (H5N1), and A/FPV/Rostock (H7N1)) or the envelope glycoprotein of MLV or LASV were Ifitm3 Attenuates Influenza In Vivo PLOS Pathogens | www.plospathogens.orgprepared as previously described [11, 28] . Ifitm-expressing MEFs were incubated with pseudoviral particles by spin-inoculation at 40006g for 30 minutes at 4uC. Cells were washed and returned to growth medium. 48 hours later, cells were harvested, fixed in 1% paraformaldehyde, and GFP expression was quantified by flow cytometry.
Western blots
RAW264.7 cells and 3T3 cells were incubated with varying concentrations of IFNa2 (eBioscience), IFNc2 (Antigenix America), IFNc (Antigenix America), IL-6 (Sigma), or OSM (Sigma). Two days later, cells were lysed with 1% NP40 and lysates were analyzed by SDS-PAGE and western blot. Goat anti-mouse Ifitm3 antibody (R & D systems) and HRP-conjugated rabbit anti-goat IgG secondary antibody (Sigma) were used to detect the expression of Ifitm3. Murine anti-b-tubulin antibody (Sigma) and HRPconjugated rabbit anti-mouse IgG secondary antibody (Santa Cruz Biotechnology) were used to measure the expression of tubulin as a loading control. Expression of myc-tagged murine Ifitms was determined using the monoclonal 9E10 antibody (Santa Cruz Biotechnology). 
Flow cytometry
Promoter activity assays
Brightfield immunohistochemistry for Ifitm3 was carried out with similar slide preparation and primary antibodies. Secondary labeling and detection were performed with biotinylated horse anti-rabbit, avidin/biotin/peroxidase complex, and Nova Red chromagen (Vector Labs). Digital images were color balanced for publication. 
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